PMID- 36031535
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230213
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Feb
TI  - Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal 
      Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint 
      Inhibitors.
PG  - 136-145
LID - S1558-7673(22)00169-0 [pii]
LID - 10.1016/j.clgc.2022.08.001 [doi]
AB  - OBJECTIVES: To clarify the impact of body mass index (BMI) on treatment outcomes 
      including survival, tumor response, and adverse events (AEs) in patients with 
      advanced renal cell carcinoma (RCC) or urothelial carcinoma (UC) treated with 
      immune checkpoint inhibitors (ICIs) in an Asian population. METHODS: We 
      retrospectively evaluated 309 patients with advanced RCC or UC who received ICIs 
      between September 2016 and July 2021. The patients were divided into high- (i.e., 
      >/=25 kg/m(2)) and low-BMI (<25 kg/m(2)) groups according to the BMI at the time of 
      treatment initiation. RESULTS: Overall, 57 patients (18.4%) were classified into 
      the high-BMI group. In RCC patients treated with ICIs as first-line therapy or UC 
      treated with pembrolizumab, progression-free survival (PFS) (p = 0.309; 
      p = 0.842), overall survival (OS) (p = 0.701; p = 0.983), and objective response 
      rate (ORR) (p = 0.163; p = 0.553) were comparable between the high- and low-BMI 
      groups. In RCC patients treated with nivolumab monotherapy as later-line therapy, 
      OS (p = 0.101) and ORR (p = 0.102) were comparable, but PFS was significantly 
      longer in the high-BMI group (p = 0.0272). Further, multivariate analysis showed 
      that BMI was not an independent factor of PFS or OS in all the treatment groups 
      (any, p>0.05). As for AE profiles, in nivolumab monotherapy, the rate was 
      significantly higher in the high-BMI group (p = 0.0203), whereas in the other two 
      treatments, the rate was comparable. CONCLUSIONS: BMI was not associated with 
      survival or response rates of advanced RCC or UC patients treated with ICIs in an 
      Asian population. AEs might frequently develop in high-BMI patients with RCC in 
      nivolumab monotherapy.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Ishihara, Hiroki
AU  - Ishihara H
AD  - Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 
      Adachi-ku, Tokyo, Japan. Electronic address: ishihara.hiroki@twmu.ac.jp.
FAU - Ishiyama, Yudai
AU  - Ishiyama Y
AD  - Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 
      Adachi-ku, Tokyo, Japan; Department of Urology, Tokyo Women's Medical University, 
      Shinjuku-ku, Tokyo, Japan.
FAU - Nemoto, Yuki
AU  - Nemoto Y
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan; Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, 
      Saitama, Japan.
FAU - Nakamura, Kazutaka
AU  - Nakamura K
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan; Department of Urology, Jyoban Hospital, Iwaki, Fukushima, Japan.
FAU - Tachibana, Hidekazu
AU  - Tachibana H
AD  - Department of Urology, Saiseikai Kurihashi Hospital, Kuki, Saitama, Japan.
FAU - Fukuda, Hironori
AU  - Fukuda H
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Yoshida, Kazuhiko
AU  - Yoshida K
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Kobayashi, Hirohito
AU  - Kobayashi H
AD  - Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 
      Adachi-ku, Tokyo, Japan.
FAU - Iizuka, Junpei
AU  - Iizuka J
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Shimmura, Hiroaki
AU  - Shimmura H
AD  - Department of Urology, Jyoban Hospital, Iwaki, Fukushima, Japan.
FAU - Hashimoto, Yasunobu
AU  - Hashimoto Y
AD  - Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Saitama, 
      Japan.
FAU - Tanabe, Kazunari
AU  - Tanabe K
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Kondo, Tsunenori
AU  - Kondo T
AD  - Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 
      Adachi-ku, Tokyo, Japan.
FAU - Takagi, Toshio
AU  - Takagi T
AD  - Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220806
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 31YO63LBSN (Nivolumab)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - Nivolumab/adverse effects
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Carcinoma, Transitional Cell/drug therapy
MH  - Body Mass Index
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms/chemically induced
MH  - *Kidney Neoplasms/pathology
OTO - NOTNLM
OT  - Avelumab
OT  - Axitinib
OT  - Ipilimumab
OT  - Nivolumab
OT  - Obesity
OT  - Pembrolizumab
EDAT- 2022/08/29 06:00
MHDA- 2023/02/01 06:00
CRDT- 2022/08/28 22:07
PHST- 2022/02/17 00:00 [received]
PHST- 2022/07/26 00:00 [revised]
PHST- 2022/08/03 00:00 [accepted]
PHST- 2022/08/29 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2022/08/28 22:07 [entrez]
AID - S1558-7673(22)00169-0 [pii]
AID - 10.1016/j.clgc.2022.08.001 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2023 Feb;21(1):136-145. doi: 10.1016/j.clgc.2022.08.001. 
      Epub 2022 Aug 6.